147 related articles for article (PubMed ID: 16703305)
1. Serious doubts on safety and efficacy of CCR5 antagonists : CCR5 antagonists teeter on a knife-edge.
Horster S; Goebel FD
Infection; 2006 Apr; 34(2):110-3. PubMed ID: 16703305
[No Abstract] [Full Text] [Related]
2. CCR5 antagonists: comparison of efficacy, side effects, pharmacokinetics and interactions--review of the literature.
Emmelkamp JM; Rockstroh JK
Eur J Med Res; 2007 Oct; 12(9):409-17. PubMed ID: 17933722
[TBL] [Abstract][Full Text] [Related]
3. [Secondary effects of treatment with maraviroc and other CCR5 antagonists. Potential impact of the CCR5 blocker].
Arribas López JR
Enferm Infecc Microbiol Clin; 2008 Oct; 26 Suppl 11():23-7. PubMed ID: 19133218
[TBL] [Abstract][Full Text] [Related]
4. CCR5 antagonists in the treatment of treatment-naive patients infected with CCR5 tropic HIV-1.
Bredeek UF; Harbour MJ
Eur J Med Res; 2007 Oct; 12(9):427-34. PubMed ID: 17933724
[TBL] [Abstract][Full Text] [Related]
5. Two new drugs for HIV infection.
Med Lett Drugs Ther; 2008 Jan; 50(1277):2-4. PubMed ID: 18197163
[No Abstract] [Full Text] [Related]
6. [New antiretroviral drug classes in HIV therapy].
Lehmann C; Meuer K; Kümmerle T; Fätkenheuer G
MMW Fortschr Med; 2009 Apr; 151(18):64-6. PubMed ID: 19769081
[No Abstract] [Full Text] [Related]
7. [CCR5 antagonists: a new class of antiretrovirals].
de la Tribonnière X; Yazdanpanah Y; Reynes J
Med Mal Infect; 2008 Mar; 38 Suppl 1():S1-6. PubMed ID: 18455055
[TBL] [Abstract][Full Text] [Related]
8. FDA notifications. Maraviroc approved as a CCR5 co-receptor antagonist.
AIDS Alert; 2007 Sep; 22(9):103. PubMed ID: 18411462
[No Abstract] [Full Text] [Related]
9. Something new under the sun. Maraviroc poised for approval.
Huff B
GMHC Treat Issues; 2006; 20(8-12):1-4. PubMed ID: 17569160
[No Abstract] [Full Text] [Related]
10. Treatment of HIV infection with the CCR5 antagonist maraviroc.
Kromdijk W; Huitema AD; Mulder JW
Expert Opin Pharmacother; 2010 May; 11(7):1215-23. PubMed ID: 20402558
[TBL] [Abstract][Full Text] [Related]
11. Maraviroc: a new CCR5 antagonist.
Sayana S; Khanlou H
Expert Rev Anti Infect Ther; 2009 Feb; 7(1):9-19. PubMed ID: 19622053
[TBL] [Abstract][Full Text] [Related]
12. CCR5 antagonists in the treatment of treatment-experienced patients infected with CCR5 tropic HIV-1.
Lorenzen T; Stoehr A; Walther I; Plettenberg A
Eur J Med Res; 2007 Oct; 12(9):419-25. PubMed ID: 17933723
[TBL] [Abstract][Full Text] [Related]
13. [Pretreated HIV patients profit from Maraviroc. Oral HIV fusion inhibitor opens new therapy chances].
MMW Fortschr Med; 2008 Apr; 150 Spec No 1():52-3. PubMed ID: 19024918
[No Abstract] [Full Text] [Related]
14. Drug safety evaluation of maraviroc for the treatment of HIV infection.
Wasmuth JC; Rockstroh JK; Hardy WD
Expert Opin Drug Saf; 2012 Jan; 11(1):161-74. PubMed ID: 22118500
[TBL] [Abstract][Full Text] [Related]
15. Concurrent use of statins does not influence efficacy of maraviroc in Maraviroc versus Optimized Therapy in Viremic Antiretroviral Treatment-Experienced Patients 1 and 2 trials.
Moyle G; Rajicic N; Goodrich J; Mayer H; Valdez H
AIDS; 2009 Jul; 23(12):1613. PubMed ID: 19622911
[No Abstract] [Full Text] [Related]
16. Maraviroc: integration of a new antiretroviral drug class into clinical practice.
Vandekerckhove L; Verhofstede C; Vogelaers D
J Antimicrob Chemother; 2008 Jun; 61(6):1187-90. PubMed ID: 18400807
[TBL] [Abstract][Full Text] [Related]
17. CCR5 antagonists in the treatment of HIV-infected persons: is their cancer risk increased, decreased, or unchanged.
McNiff T; Dezube BJ
AIDS Read; 2009; 19(6):218-22, 224. PubMed ID: 19642239
[No Abstract] [Full Text] [Related]
18. Novel CCR5 antagonists for the treatment of HIV infection: a review of compounds patented in 2006 - 2008.
Yang H; Rotstein DM
Expert Opin Ther Pat; 2010 Mar; 20(3):325-54. PubMed ID: 20180619
[TBL] [Abstract][Full Text] [Related]
19. When and how to use maraviroc in HIV-infected patients.
Soriano V; Perno CF; Kaiser R; Calvez V; Gatell JM; di Perri G; Pillay D; Rockstroh J; Geretti AM
AIDS; 2009 Nov; 23(18):2377-85. PubMed ID: 19834318
[No Abstract] [Full Text] [Related]
20. Antiviral activity and safety of aplaviroc with lamivudine/zidovudine in HIV-infected, therapy-naive patients: the ASCENT (CCR102881) study.
Currier J; Lazzarin A; Sloan L; Clumeck N; Slims J; McCarty D; Steel H; Kleim JP; Bonny T; Millard J;
Antivir Ther; 2008; 13(2):297-306. PubMed ID: 18505181
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
